Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation

doi:10.3748/wjg.121126

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 45

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 7, 2026; 32(45): 121126
Published online Dec 7, 2026. doi: 10.3748/wjg.121126

Full Size Figure Download Figure

Figure 1 Flowchart of patient selection, grouping, and follow-up outcomes in this study. LT: Liver transplantation; NET: Neuroendocrine tumor; NETLM: Neuroendocrine tumor liver metastasis; GEP: Gastroenteropancreatic; MDT: Multidisciplinary team; IS: Immunosuppression; PRRT: Peptide receptor radionuclide therapy; NYHA: New York Heart Association; eGFR: Estimated glomerular filtration rate; WHO: World Health Organization; IHC: Immunohistochemistry; ⁶⁸Ga-DOTATATE: Gallium-68 dotatate; SSTR: Somatostatin receptor; PET/CT: Positron emission tomography/computed tomography.

Citation: Zheng QM, Chen CY, Zhang L, Sun JS, Wang HH, Xie Y, Guo QJ, Jiang WT. Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation. World J Gastroenterol 2026; 32(45): 121126
URL: https://www.wjgnet.com/1007-9327/full/v32/i45/121126.htm
DOI: https://dx.doi.org/10.3748/wjg.121126

Zheng QM, Chen CY, Zhang L, Sun JS, Wang HH, Xie Y, Guo QJ, Jiang WT. Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation. World J Gastroenterol 2026; 32(45): 121126 [DOI: 10.3748/wjg.121126]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.